PROTO SCRIPT PHARMACEUTICAL CORP
CIK 0001521420
Revenue (TTM)
$0
Q3 Mar 2018
Net Income (TTM)
−$1.12M
−21,571.9% YoY
Q3 Mar 2018
EPS Diluted (TTM)
—
Q3 Mar 2018
Gross Margin
—
Q3 Mar 2018
Operating Margin
—
Q3 Mar 2018
Net Margin
—
Q3 Mar 2018
Free Cash Flow (TTM)
−$32.59K
Q3 Mar 2018
Cash
$0
Q3 Mar 2018
Total Debt
—
Q3 Mar 2018
Shares Outstanding
49.14M sh
Q3 Mar 2018
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.